Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sino Medical Sciences Technology Inc. (688108.SS)
Tianjin, CN
Sino Medical Sciences Technology Inc. operates as a medical device enterprise, specializing in the research, development, manufacturing, and distribution of interventional medical devices throughout China. Its product portfolio features a range of crucial items, including drug-eluting stents, balloon catheters, coronary stents, and sophisticated transcatheter mitral valve replacement devices. Furthermore, the company maintains a clinical partnership with The National University of Ireland Galway. Established in 2007, its main operational base is situated in Tianjin, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +20.02% | +11.56% | +4.01% | -0.09% | +17.62% | +15.90% | +101.81% | +113.81% | +143.18% | +0.41% | +0.41% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2025-09 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+14.5% ★ Q1'26: +38.6% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+2,650.0% ★ Q1'26: +485.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+9.3% ★ Q1'26: +7.3% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+13.0% ★ Q1'26: +20.6% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+6.8% ★ Q1'26: +12.4% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+14.8% Q1'26: +40.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.97× ★ Q1'26: 1.22× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
343.26M
est: 309.00M (+11.1%)
|
458.74M
est: 475.00M (-3.4%)
|
525.41M
est: 573.00M (-8.3%)
|
745.00M
745.00M – 745.00M
+30.0% YoY
|
969.00M
969.00M – 969.00M
+30.1% YoY
|
| EBITDA |
-13.01M
est: -82.22M (+84.2%)
|
53.27M
est: -104.52M (+151.0%)
|
133.04M
est: -126.08M (+205.5%)
|
-163.93M
-163.93M – -163.93M
-30.0% YoY
|
-213.21M
-213.21M – -213.21M
-30.1% YoY
|
| EBIT |
-63.93M
est: -130.58M (+51.0%)
|
-11.33M
est: -181.23M (+93.8%)
|
68.45M
est: -218.62M (+131.3%)
|
-284.25M
-284.25M – -284.25M
-30.0% YoY
|
-369.71M
-369.71M – -369.71M
-30.1% YoY
|
| Net Income |
-39.63M
est: -56.17M (+29.4%)
|
1.50M
est: 12.90M (-88.4%)
|
47.29M
est: 34.39M (+37.5%)
|
60.18M
60.18M – 60.18M
+75.0% YoY
|
81.68M
81.68M – 81.68M
+35.7% YoY
|
| SGA |
157.45M
est: 179.16M (-12.1%)
|
168.07M
est: 247.43M (-32.1%)
|
55.96M
est: 298.48M (-81.3%)
|
388.08M
388.08M – 388.08M
+30.0% YoY
|
504.77M
504.77M – 504.77M
+30.1% YoY
|
| EPS |
-0.10
est: -0.15 (+33.3%)
|
0.00
est: 0.03 (-86.7%)
|
0.11
est: 0.08 (+37.5%)
|
0.14
0.14 – 0.14
+75.0% YoY
|
0.19
0.19 – 0.19
+35.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.77% | 540.5K | 0.95% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jianhua Sun | Chairman & GM | — | male |
| Kai Huang | Board Secretary & Director | — | male |
| Lihua Shen | Chief Financial Officer & Director | — | female |
| Liye Cui | Deputy General Manager of Production & Operation | — | male |
| Meihong Li | Accounting Supervisor | — | — |
| Tianzhu Li | Core Technical Personnel | — | male |
| Xiaoran Kang | Deputy GM & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688108.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
